medigraphic.com
ISSN 2078-7170 (Digital)

2012, Número 2

Siguiente >>

CorSalud 2012; 4 (2)


Prevención secundaria en la enfermedad coronaria en 2012: Análisis de algunos aspectos más allá de la prescripción de fármacos

Mele EF

Idioma: Español
Referencias bibliográficas: 33
Paginas: 80-86
Archivo PDF: 135.44 Kb.


FRAGMENTO

Entendemos por normas de prevención secundaria en enfermedad coronaria, a aquellas medidas terapéuti-cas, farmacológicas o no, que se implementan en los pacientes que ya han sufrido un síndrome coronario, con el objetivo de disminuir la incidencia de muerte y nuevos sucesos en su seguimiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Smith S, Benjamin E, Bonow R, Braun L, Creager M, Barry F, Franklin A, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. JACC. 2011;58(23):2432-46.

  2. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R. European Guidelines on Car-diovascular Diseases in Clinical Practice. Eur J Car-diovasc Prev Rehabil. 2007;14(Suppl2):S1-S113.

  3. Consenso de Prevención de la Sociedad Argentina de Cardiología. Rev Argent Cardiol. 2012 (En prensa).

  4. The Action to Control Cardiovascular Risk in Dia-betes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.

  5. Duckworth W, Abraira C, Moritz T, Reda D, Ema-nuele N, Reaven PD, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39.

  6. ADVANCE Collaborative Group, Patel A, Mac-Mahon S, Chalmers J, Neal B, Billot L, et al. Inten-sive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72.

  7. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-72.

  8. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data. Ann Intern Med. 2002;136(6):438-48.

  9. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hyperten-sive Patients with Coronary Artery Disease Be Dan-gerous? Ann Intern Med. 2006;144(12):884-93.

  10. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of Intensive Blood-Pressure Control in Type 2 Dia-betes Mellitus. N Engl J Med. 2010;362(17):1575-85.

  11. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients with Diabetes and Coronary Heart Disease. JAMA. 2010;304(1):61-8.

  12. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Cooper-Dehoff RM, Handberg EM, et al. Charac-teristics and Outcomes of Revascularized Patients With Hypertension: An International Verapamil SR-Trandolapril Substudy. Hypertension. 2009;53(4): 624-30.

  13. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease: Findings From the INternationalVErapamil-SR/Trandolapril Study. Hypertension. 2010;55(1);48-53.

  14. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM Jr, Cooper-Dehoff RM, Handberg EM. Coronary Re-vascularization Strategy and Outcomes According to Blood Pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498-503.

  15. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31(23):2897-908.

  16. Wenger NK, MACP, FACC, FAHA. Current Status of Cardiac Rehabilitation. J Am Coll Cardiol. 2008; 51:1619-31.

  17. Spiegel PB, Salama P. War and mortality in Koso-vo, 1998-99: an epidemiological testimony. Lancet. 2000;355 (9222):2204-09.

  18. Oosterhoff P, Zwanikken P, Ketting E. Sexual torture of men in Croatia and other conflict situa-tions: an open secret. Reprod Health Matters. 2004; 12(23):68-77.

  19. Phillips DP, Jarvinen JR, Abramson IS, Phillips RR. Cardiac mortality is higher around Christmas and New Years´ than at any other time. The holidays as a risk factor for death. Circulation 2004;110(25): 3781-88.

  20. Goldberg RJ, Spencer F, Leesard D, Yarzebsky J, Lareau C, Gore JM. Occurrence of acute myocar- dial infarction in Worcester Massachusetts before, during, and after the terrorist attacks in New York City and Washington, DC, on September 11 2001. Am J Cardiol. 2005;95(2):258-60.

  21. Stalnikowicz R, Tsafrir A. Acute psychosocial stress and cardiovascular events. American Journal of Emergency Medicine. 2002;20(5):488-91.

  22. Sosa Liprandi MI, Racki M, Khoury M, Villarreal R, Cestari G, Mele E, Sosa Liprandi A. Crisis económi-co-financieras en Argentina: ¿Un nuevo factor de riesgo de mortalidad cardiovascular? Rev Argent Cardiol. 2012 (En prensa).

  23. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-Based Rehabilitation for Patients with Coronary Heart Disease: Systematic Review and Meta-analysis of Randomized Con-trolled Trials. Am J Med. 2004;116(10):682-692.

  24. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease. Ann Intern Med. 2005;143(9):659-72.

  25. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, et al. Core Components of Cardiac Rehabilitation/Secondary Prevention Pro-grams: 2007 Update. Circulation. 2007;115(20): 2675-82.

  26. Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Out-comes. Circulation. 2009;119(23):3028-35.

  27. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-Term Adherence to Evidence-Based Secondary Preven-tion Therapies in Coronary Artery Disease. Circula-tion. 2006;113(2);203-12.

  28. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardio-protective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37.

  29. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight Euro-pean countries. Lancet. 2009;373 (9667):929-40.

  30. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ. Impact of Medication Therapy Dis-continuation on Mortality After Myocardial Infarction. Arch Intern Med. 2006;166(17):1842-47.

  31. Niu S, Zhao D, Zhu J, Liu J, Liu Q, Liu J, et al. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China:Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. Am Heart J. 2009;157(4):709-15.

  32. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended Consequences of Caps on Medicare Drug Benefits. N Engl J Med. 2006; 354(22):2349-59.

  33. Yusuf S, Islam S, Chow C, Rangarajan S, Dage-nais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epide-miological survey. Lancet. 2011;378 (9798):1231-43.




2020     |     www.medigraphic.com